Glucosio Baxter

Glucosio Baxter is an intravenous solution that contains glucose as the active ingredient. It is supplied as a sterile liquid for parenteral administration and is marketed in the European Union. The product supplies exogenous glucose to support energy metabolism and to raise plasma glucose levels during fluid and electrolyte replacement or parenteral nutrition.

Glucosio Baxter is used in clinical settings where rapid glucose supplementation and fluid balance are required.

- Treatment of hypoglycemia when oral intake is not feasible, providing immediate glucose support. - Component of fluid and electrolyte replacement regimens for postoperative, trauma, or burn patients. - Source of carbohydrate calories in parenteral nutrition formulations for patients unable to eat. - Support of energy metabolism during prolonged fasting, critical illness, or major surgery. - Adjunct in diagnostic procedures that require controlled glucose infusion to maintain stable plasma levels.

Adverse reactions to Glucosio Baxter are generally related to the intravenous administration of a carbohydrate solution.

Common: - Mild hyperglycemia, especially in patients with impaired glucose tolerance. - Local irritation at the infusion site, such as erythema, pain, or swelling. - Electrolyte shifts, most commonly a transient decrease in serum potassium. - Nausea or vomiting associated with rapid infusion rates. - Transient increase in serum osmolality causing mild thirst.

Serious: - Severe hyperglycemia leading to osmotic diuresis and dehydration. - Allergic reactions ranging from urticaria to anaphylaxis. - Fluid overload causing pulmonary edema in patients with compromised cardiac function. - Metabolic acidosis when large volumes are infused without adequate buffering. - Severe electrolyte disturbances requiring urgent medical intervention.

When prescribing Glucosio Baxter, clinicians should evaluate patient-specific factors and monitor relevant parameters.

- Assess baseline blood glucose levels before and during infusion to avoid hyper- or hypoglycemia. - Adjust infusion rate in patients with renal or hepatic impairment due to altered glucose metabolism. - Use caution in individuals with heart failure or risk of fluid overload; monitor volume status closely. - Monitor electrolytes, particularly potassium and sodium, throughout therapy. - Avoid rapid bolus administration unless specifically indicated, to reduce risk of cardiovascular stress. - Verify compatibility with other intravenous solutions to prevent precipitation or incompatibility reactions. - Document any signs of allergic response and be prepared to discontinue infusion if severe reactions occur.

Glucosio Baxter may interact with other medications or solutions administered intravenously.

Avoid: - Concurrent use with insulin infusions without dose adjustment, which can cause severe hypoglycemia. - Co‑administration with potassium‑containing solutions that may precipitate when mixed with high‑glucose concentrations. - Simultaneous infusion of calcium salts that can form insoluble complexes.

Use with caution: - Concurrent diuretics that alter fluid balance, requiring close monitoring of volume status. - Vasopressors that affect peripheral perfusion, potentially influencing glucose delivery. - Anticoagulants, as rapid infusion may affect coagulation parameters in susceptible patients. - Beta‑blockers, which may mask signs of hypoglycemia during glucose infusion. - Other hypertonic solutions, which may increase the risk of osmotic shifts if combined.